Expression Microarray Meta-Analysis Identifies Genes Associated with Ras/MAPK and Related Pathways in Progression of Muscle-Invasive Bladder Transition Cell Carcinoma

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Ewald, Jonathan A ^a,b   Downs, Tracy M ^a,b   Cetnar, Jeremy P ^a,b   Ricke, William A ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 10; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CDC25C GENE; CLINICAL ARTICLE; COL11A1 GENE; COL3A1 GENE; COL5A1 GENE; CONTROLLED STUDY; ERBB3 GENE; FN1 GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAPK10 GENE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TUMOR GENE;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; COMPUTATIONAL BIOLOGY; FIBRILLAR COLLAGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SKELETAL; NEOPLASM INVASIVENESS; RAS PROTEINS; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84873263079     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055414     Document Type: Article

References (37)

1. Howlander Nea (2012) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD, USA: National Cancer Institute.
2. Knowles MA, (2001) What we could do now: molecular pathology of bladder cancer. Mol Pathol 54: 215-221.
3. McConkey DJ, Lee S, Choi W, Tran M, Majewski T, et al. (2010) Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol 28: 429-440.
4. Wu XR, (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5: 713-725.
5. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, et al. (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5: e13821.
6. Simon R, (2008) Microarray-based expression profiling and informatics. Curr Opin Biotechnol 19: 26-29.
7. Eisen MB, Spellman PT, Brown PO, Botstein D, (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.
8. Zhang B, Kirov S, Snoddy J, (2005) WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33: W741-748.
9. Ananiadou S, Pyysalo S, Tsujii J, Kell DB, (2010) Event extraction for systems biology by text mining the literature. Trends Biotechnol 28: 381-390.
10. Jenssen TK, Laegreid A, Komorowski J, Hovig E, (2001) A literature network of human genes for high-throughput analysis of gene expression. Nat Genet 28: 21-28.
11. Chen H, Sharp BM, (2004) Content-rich biological network constructed by mining PubMed abstracts. BMC Bioinformatics 5: 147.
12. Faro A, Giordano D, Spampinato C, (2012) Combining literature text mining with microarray data: advances for system biology modeling. Brief Bioinform 13: 61-82.
13. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, et al. (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9: 166-180.
14. Dietzsch J, Gehlenborg N, Nieselt K, (2006) Mayday-a microarray data analysis workbench. Bioinformatics 22: 1010-1012.
15. Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, et al. (2012) Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 18: 1323-1333.
16. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, et al. (2005) Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 11: 4044-4055.
17. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, et al. (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64: 4040-4048.
18. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, et al. (2003) Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33: 90-96.
19. Dyrskjot L, Zieger K, Real FX, Malats N, Carrato A, et al. (2007) Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 13: 3545-3551.
20. Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, et al. (2004) Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res 10: 3410-3421.
21. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C, (2006) Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24: 778-789.
22. Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SG, et al. (2006) Regional copy number-independent deregulation of transcription in cancer. Nat Genet 38: 1386-1396.
23. Ewald JA, Jarrard DF, (2012) Decreased skp2 expression is necessary but not sufficient for therapy-induced senescence in prostate cancer. Transl Oncol 5: 278-287.
24. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6.
25. Aressy B, Ducommun B, (2008) Cell cycle control by the CDC25 phosphatases. Anticancer Agents Med Chem 8: 818-824.
26. Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T, et al. (2006) The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer 94: 1703-1709.
27. Eissa S, Zohny SF, Zekri AR, El-Zayat TM, Maher AM, (2010) Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence. Med Oncol 27: 1286-1294.
28. Gritsenko PG, Ilina O, Friedl P, (2012) Interstitial guidance of cancer invasion. J Pathol 226: 185-199.
29. Wenstrup RJ, Smith SM, Florer JB, Zhang G, Beason DP, et al. (2011) Regulation of collagen fibril nucleation and initial fibril assembly involves coordinate interactions with collagens V and XI in developing tendon. J Biol Chem 286: 20455-20465.
30. Collier IE, Legant W, Marmer B, Lubman O, Saffarian S, et al. (2011) Diffusion of MMPs on the surface of collagen fibrils: the mobile cell surface-collagen substratum interface. PLoS One 6: e24029.
31. Juliano RL, Reddig P, Alahari S, Edin M, Howe A, et al. (2004) Integrin regulation of cell signalling and motility. Biochem Soc Trans 32: 443-446.
32. Zoppi N, Gardella R, De Paepe A, Barlati S, Colombi M, (2004) Human fibroblasts with mutations in COL5A1 and COL3A1 genes do not organize collagens and fibronectin in the extracellular matrix, down-regulate alpha2beta1 integrin, and recruit alphavbeta3 Instead of alpha5beta1 integrin. J Biol Chem 279: 18157-18168.
33. Exposito JY, Valcourt U, Cluzel C, Lethias C, (2011) The fibrillar collagen family. Int J Mol Sci 11: 407-426.
34. Cabodi S, Moro L, Bergatto E, Boeri Erba E, Di Stefano P, et al. (2004) Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. Biochem Soc Trans 32: 438-442.
35. Citri A, Yarden Y, (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516.
36. Resat H, Ewald JA, Dixon DA, Wiley HS, (2003) An integrated model of epidermal growth factor receptor trafficking and signal transduction. Biophys J 85: 730-743.
37. Turjanski AG, Vaque JP, Gutkind JS, (2007) MAP kinases and the control of nuclear events. Oncogene 26: 3240-3253.